Avaleht › Ülekaalulisus › Arizona › Tucson
Ülekaalulisus kliinilised uuringud linnas Tucson, AZ
15 uuringut haiguse Ülekaalulisus jaoks otsivad osalejaid linnas Tucson ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
VärbamineFaas 3
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
VärbamineFaas 3
- University of Arizona, Tucson
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
VärbamineFaas 3
- Tucson Clinical Research Institute, Tucson
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
VärbamineFaas 3
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
VärbamineFaas 3
- Research Site, Tucson
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
VärbamineFaas 3
- Tucson Orthopaedic Institute - North Wyatt Drive, Tucson
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
VärbamineFaas 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
VärbamineFaas 3
- AURORA-1 Clinical Site, Tucson
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
VärbamineFaas 3
- AURORA-2 Clinical Site, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
VärbamineFaas 3
- Arizona Clinical Trials, Tucson
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
VärbamineFaas 3
- Arizona Clinical Trials, Tucson
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
VärbamineFaas 3Terved vabatahtlikud oodatud
- ACCOMPLISH-2 Research Site, Tucson
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
VärbamineFaas 2
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
VärbamineFaas 2
- Pima Heart, Tucson
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
VärbamineFaas 3
- ACCOMPLISH-1 Research Site, Tucson
Ülekaalulisus uuringud teistes linnades
- San Antonio, TX34 uuringut
- Houston, TX33 uuringut
- Chicago, IL28 uuringut
- Orlando, FL27 uuringut
- Las Vegas, NV23 uuringut
- Miami, FL23 uuringut
- Atlanta, GA20 uuringut
- Dallas, TX20 uuringut
- New York City, NY19 uuringut
- Jacksonville, FL19 uuringut
- Washington, DC19 uuringut
- Austin, TX18 uuringut
Muud uuringud linnas Tucson
- Rinnavähk20 uuringut
- Mitteväikerakuline kopsuvähk17 uuringut
- Rasvumine17 uuringut
- Metastaatiline vähk14 uuringut
- Vähk (kõik liigid)12 uuringut
- Kardiovaskulaarsed haigused12 uuringut
- Käär- ja pärasoolevähk11 uuringut
- Eesnäärmevähk11 uuringut
- Steatoosne maksahaigus10 uuringut
- Südamepuudulikkus10 uuringut
- Kõrge vererõhk10 uuringut
- 2. tüüpi diabeet10 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.